G1 Therapeutics Inc. said March 7 that it priced its underwritten public offering of 3.4 million common shares at $29.50 apiece.
The company expects to raise gross proceeds of $100.3 million through the offering, which is expected to close March 12, subject to customary closing conditions.
Additionally, G1 Therapeutics granted underwriters a 30-day option to buy up to an additional 510,000 shares at the offering price.
J.P. Morgan Securities LLC and Cowen and Co. LLC are acting as joint book-running managers for the offering, with Needham & Co. LLC and Wedbush Securities Inc. as lead managers and BTIG LLC as co-manager.
North Carolina-based G1 Therapeutics develops novel cancer therapies.
